EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines

Autor(es):Mostrar menos -

Lobo, Yara A. ^[1] ; Bonazza, Camila ^[2] ; Batista, Fabricio P. ^[1] ; Castro, Rodrigo A. ^[2] ; Bonturi, Camila R. ^[1] ; Salu, Bruno R. ^[1] ; Sinigaglia, Rita de Cassia ^[3] ; Toma, Leny ^[1] ; Vicente, Carolina M. ^[1] ; Pidde, Giselle ^[4] ; Tambourgi, V, Denise ; Alvarez-Flores, Miryam P. ^[5] ; Chudzinski-Tavassi, Ana M. ^[5] ; Oliva, V, Maria Luiza

Afiliação do(s) autor(es)

^[1] V, Univ Fed Sao Paulo, Biochem, BR-04044020 Sao Paulo, SP - Brazil

^[2] Univ Fed Sao Paulo, Gynecol, BR-04044020 Sao Paulo, SP - Brazil

^[3] Univ Fed Sao Paulo, Electron Microscopy Ctr, BR-04044020 Sao Paulo, SP - Brazil

^[4] V, Inst Butantan, Immunochem, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP - Brazil

^[5] Inst Butantan, Ctr Excellence New Target Discovery CENTD, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Cancer Letters; v. 491, p. 108-120, OCT 28 2020.
• Citações Web of Science: 0

Resumo

Breast cancer is the most common malignant tumor among women worldwide, and triple-negative breast cancer is the most aggressive type of breast cancer, which does not respond to hormonal therapies. The protease inhibitor, EcTI, extracted from seeds of Enterolobium contortisiliquum, acts on the main signaling pathways of the MDA-MB-231 triple-negative breast cancer cells. This inhibitor, when bound to collagen I of the extracellular matrix, triggers a series of pathways capable of decreasing the viability, adhesion, migration, and invasion of these cells. This inhibitor can interfere in the cell cycle process through the main signaling pathways such as the adhesion, Integrin/FAK/SRC, Akt, ERK, and the cell death pathway BAX and BCL-2. It also acts by reducing the main inflammatory cytokines such as TGF-alpha, IL-6, IL-8, and MCP-1, besides NF kappa B, a transcription factor, responsible for the aggressive and metastatic characteristics of this type of tumor. Thus, the inhibitor was able to reduce the main processes of carcinogenesis of this type of cancer. (AU)

• Processo FAPESP: 17/06630-7 - Fragmentos derivados de proteínas com seletividade para inibição de enzimas de mamíferos e micro-organismos e seu papel como agente anti-inflamatório, antimicrobiano, antitrombótico e antitumoral: mecanismo de ação
• Beneficiário: Maria Luiza Vilela Oliva
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/07972-9 - Desenvolvimento de compostos para profilaxia e tratamento de doenças cardiovasculares
• Beneficiário: Maria Luiza Vilela Oliva
• Modalidade de apoio: Auxílio à Pesquisa - Regular